When medicine exists but access to it requires bureaucratic endurance, the gap between knowledge and care becomes its own kind of harm. New Zealand's Pharmac has moved to close that gap for patients facing multidrug-resistant bacterial infections and the dangerous blood pressure crises of spinal cord injury, funding four medicines under clearer rules from November 2026. The change is administrative in form but deeply human in consequence — removing the paperwork that once stood between a clinician's judgment and a patient's need.
Pharmac expands access to antibiotics for drug-resistant infections, blood pressure management
People with multidrug-resistant bacterial infections and spinal cord injuries experiencing autonomic dysreflexia will have improved access to life-managing treatments.
Clinicians spend less time on paperwork, more time on patients
Mark
Why does it matter that these medicines move from exceptional funding to the regular schedule?
Mimi
Because right now, a clinician has to make a case for each patient individually. That takes time and creates uncertainty. Moving to the schedule means the decision is already made—if you meet the criteria, you get the medicine.
Luke
But we should be clear: some patients were already getting these medicines through the exceptional process. This isn't creating access from nothing. It's streamlining access that already existed for a few.
Mark
So who benefits most from this change?
Mimi
Patients with multidrug-resistant infections who have limited options, and people with spinal cord injuries dealing with autonomic dysreflexia. For the second group especially, being able to manage blood pressure episodes at home instead of going to hospital is genuinely life-changing.
Luke
That's the claim, anyway. We don't have data yet on how many emergency visits will actually be prevented or how many patients will use the captopril this way.
Mark
What about the clinicians—what's their stake in this?
Mimi
They spend less time filling out paperwork and more time treating patients. That's not trivial. Exceptional funding applications take real effort.
Luke
True, but we should note that the administrative burden reduction is Pharmac's framing. We don't have independent confirmation of how much time clinicians actually spend on these applications or how much this change will free up.
Mark
When does this actually take effect?
Mimi
November 1, 2026. So patients and clinicians have a few weeks to adjust.
Luke
And the feedback Pharmac received was "broadly supportive"—which is vague. We don't know how many submissions they got, who opposed it, or what concerns were raised and not addressed.
The Pulse
- Multidrug-resistant bacterial infections and autonomic dysreflexia represent conditions where delay is not merely inconvenient — it can be fatal or permanently damaging.
- Clinicians have long faced the friction of exceptional funding applications, a case-by-case approval process that consumed time and created uneven access to treatments already known to work.
- Pharmac's November 2026 decision lists ceftolozane with tazobactam, bedaquiline, linezolid, and captopril oral liquid on the formal Pharmaceutical Schedule, replacing individual approvals with consistent, predictable access.
- For spinal cord injury patients, the expanded availability of captopril oral liquid means dangerous blood pressure episodes can be managed at home, reducing the cascade of emergency hospital visits.
- The shift signals a broader principle: that access to effective treatment should be governed by clear clinical criteria, not by a clinician's capacity to navigate bureaucratic approval.
When medicine exists but access to it requires bureaucratic endurance, the gap between knowledge and care becomes its own kind of harm. New Zealand's Pharmac has moved to close that gap for patients facing multidrug-resistant bacterial infections and the dangerous blood pressure crises of spinal cord injury, funding four medicines under clearer rules from November 2026. The change is administrative in form but deeply human in consequence — removing the paperwork that once stood between a clinician's judgment and a patient's need.
New Zealand's pharmaceutical funding authority has taken steps to untangle access to four medicines treating two serious but very different conditions — bacterial infections that resist standard antibiotics, and a dangerous complication of spinal cord injury that sends blood pressure dangerously high without warning.
From November 1, 2026, Pharmac will fund ceftolozane with tazobactam in hospital settings for patients with multidrug-resistant bacterial infections — those that no longer respond to conventional treatment. Alongside this, funded access to bedaquiline and linezolid expands for people with non-tuberculous mycobacterial infections, a rare and notoriously difficult category of bacterial disease. For spinal cord injury patients, captopril oral liquid becomes more readily available to manage autonomic dysreflexia, a condition in which the nervous system misfires and triggers sudden, severe blood pressure spikes.
The practical shift is significant: clinicians will no longer need to file Named Patient Pharmaceutical Assessment requests — the exceptional funding applications that once required individual justification and approval before these medicines could be prescribed. Pharmac's Chief Advisor for Pharmaceuticals described the change as removing friction from the system, freeing clinicians from paperwork and patients from delay.
For those living with spinal cord injuries, the change carries particular weight. Autonomic dysreflexia demands immediate intervention, and with captopril oral liquid now more accessible, patients can manage episodes at home rather than presenting to emergency departments — reducing both personal crisis and systemic burden.
Pharmac consulted publicly before finalising the decisions and reported broadly supportive feedback. The outcome reflects a clear institutional position: that access to proven treatments should rest on transparent, predictable rules rather than on the willingness of individual clinicians to navigate exceptional approval processes.
New Zealand's pharmaceutical funding authority has moved to simplify access to four medicines that treat two very different but equally serious conditions: stubborn bacterial infections that resist standard antibiotics, and a dangerous complication of spinal cord injury that causes sudden, severe blood pressure spikes.
Starting November 1, 2026, Pharmac will fund ceftolozane with tazobactam in hospital settings for patients battling multidrug-resistant bacterial infections—the kind that no longer respond to conventional treatment. The same decision expands funded access to two other antibiotics, bedaquiline and linezolid, for people with non-tuberculous mycobacterial infections, a rare category of bacterial disease that is notoriously difficult to treat. For people with spinal cord injuries, Pharmac is widening access to captopril oral liquid, a blood pressure medication that helps manage autonomic dysreflexia, a condition where the nervous system misfires and sends blood pressure dangerously high without warning.
The practical effect is straightforward but significant: clinicians will no longer need to file exceptional funding applications—known as Named Patient Pharmaceutical Assessment requests—to prescribe these medicines for eligible patients. That administrative step, which once required justification and approval for each individual case, simply disappears. Adrienne Martin, Pharmac's Chief Advisor for Pharmaceuticals, framed the change as removing friction from the system. Clinicians spend less time on paperwork and more time on patients. Patients get faster access to treatments they need.
Some of these medicines were already available through the exceptional funding pathway, but only for a small number of people and only after bureaucratic delay. By listing them on the Pharmaceutical Schedule—Pharmac's formal roster of funded treatments—the authority is essentially saying: these work, these are needed, and eligible patients should have them without jumping through hoops. The shift trades case-by-case assessment for clearer, faster access.
For people with spinal cord injuries managing autonomic dysreflexia, the change carries particular weight. The condition can trigger sudden, severe blood pressure elevation that demands immediate intervention. With captopril oral liquid now more readily available, patients can manage these episodes at home rather than rushing to hospital emergency departments. That matters not just for convenience but for the cumulative burden on both patients and the health system. Fewer emergency visits means fewer crises, more stability, more dignity in managing a chronic complication.
Pharmac consulted publicly on the proposal and reported receiving broadly supportive feedback. The authority acknowledged that input shaped the final decision, ensuring the changes would actually work for the people who depend on these medicines. The funding decisions reflect a recognition that access to treatment should not hinge on a clinician's willingness to navigate exceptional approval processes, but rather on clear, predictable rules that let doctors prescribe what patients need.
Notable Quotes
These decisions will improve access to medicines for people with serious infections and for people with spinal cord injuries who experience sudden episodes of high blood pressure while making it easier for clinicians to access funded treatments on behalf of their patients.— Adrienne Martin, Pharmac Chief Advisor, Pharmaceuticals
Reducing the need for exceptional funding applications lowers the administrative burden on clinicians and allows them to spend more time focusing on patient care.— Adrienne Martin, Pharmac Chief Advisor, Pharmaceuticals
Want the full story?
Read the original at NZDoctor ↗
Health & Medicine